Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, reports the findings of an interim analysis of the UVEA-IXA study of ixazomib-based therapy in relapsed/refractory multiple myeloma. The study enrolled 359 patients and treated them outside the clinical trial setting. Of 275 patients with evaluable outcome data, the overall response rate (ORR) was 60%. Commonly reported adverse effects were in line with those well characterized for ixazomib and were manageable. The data show that ixazomib-based therapy is an effective option in the real-world setting, agreeing with the findings of ixazomib in clinical trials. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Prof. Heinz Ludwig, MD, has received research funding from Amgen and Takeda; has been a member of a speakers bureau with Celgene, Janssen, Bristol Myers, Sanofi and Amgen; and has participated in advisory boards for Janssen, Bristol Myers, Sanofi, Amgen and Seattle Genetics.